SCHEMBL3501938

SCHEMBL3501938

CCOC(=O)c1ccc(CN2CCOCC2)o1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.66
ALDH1A1 P00352 9/20 0.62
NPSR1 Q6W5P4 2/20 0.62
HRH3 Q9Y5N1 1/20 0.56
TSHR P16473 5/20 0.56
MAPT P10636 4/20 0.56
LMNA P02545 3/20 0.56
RAB9A P51151 2/20 0.56
MAPK1 P28482 1/20 0.56
STAT3 P40763 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
HSD17B10 Q99714 1/20 0.51
KDM4E B2RXH2 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.48
TLR2 O60603 1/20 0.48
NSD2 O96028 1/20 0.48
POLB P06746 1/20 0.48
PKM P14618 1/20 0.48
MPI P34949 1/20 0.48
GRK6 P43250 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1801024 0.89 ALDH1A1 (0.65) HTTALDH1A1NPSR1HRH3TSHR
SCHEMBL25062544 0.88 ALDH1A1 (0.63) HTTALDH1A1NPSR1HRH3TSHR
SCHEMBL8242761 0.86 ALDH1A1 (0.66) HTTALDH1A1NPSR1TSHRMAPT
SCHEMBL9219870 0.84 ALDH1A1 (0.59) HTTALDH1A1NPSR1TSHRMAPT
SCHEMBL1286688 0.81 HTT (0.75) HTTALDH1A1NPSR1HRH3LMNA
SCHEMBL10397057 0.81 SMN1; SMN2 (0.80) ALDH1A1HRH3TSHRMAPTLMNA
SCHEMBL1243301 0.80 HTT (1.00) HTTALDH1A1NPSR1HRH3MAPT
Trifluoroacetic Acid SCHEMBL5305580 0.79 ALDH1A1 (0.56) HTTALDH1A1NPSR1TSHRMAPT
SCHEMBL25062911 0.79 ALDH1A1 (0.52) HTTALDH1A1NPSR1TSHRMAPT
SCHEMBL4136038 0.79 HTT (0.75) HTTALDH1A1NPSR1HRH3RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116234800-A Copper complexes for the treatment of neurodegenerative disorders ALS治疗发展学会 2023-06-06 CN disclosed
US-20230054997-A1 COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS ALS THERAPY DEVELOPMENT INSTITUTE, 2023-02-23 US disclosed
US-20100179190-A1 BICYCLIC PYRAZOLO PROTEIN KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2010-07-15 US disclosed
US-7473783-B2 Bicyclic pyrazolo protein kinase modulators SGX PHARMACEUTICALS, INC. (US) 2009-01-06 US disclosed
EP-1713814-A1 BICYCLIC PYRAZOLO-FUSED COMPOUNDS AS PROTEIN KINASE MODULATORS SGX Pharmaceuticals, Inc. (US) 2006-10-25 EP disclosed
US-20050176786-A1 Bicyclic pyrazolo protein kinase modulators STRUCTURAL GENOMIX (US) 2005-08-11 US disclosed
WO-2005068473-A1 BICYCLIC PYRAZOLO-FUSED COMPOUNDS AS PROTEIN KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2005-07-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179190-A1 BICYCLIC PYRAZOLO PROTEIN KINASE MODULATORS MAP3K20, MAP4K2, MAP4K3 HTT 4039/4885ALDH1A1 4737/4885NPSR1 4011/4885
US-20050176786-A1 Bicyclic pyrazolo protein kinase modulators MAP3K20, MAP4K2, MAP4K3 HTT 4039/4885ALDH1A1 4737/4885NPSR1 4011/4885
US-20230054997-A1 COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS SOD1, SMN1; SMN2, CLN6 HTT 9/4885ALDH1A1 1721/4885NPSR1 4242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.